PT  - JOURNAL ARTICLE
AU  - Kuznar, Wayne
ED  - Redfield, Margaret
TI  - PDE-5 Inhibition Has No Effect on Measures of Heart Failure
DP  - 2013 May 01
TA  - MD Conference Express
PG  - 19--19
VI  - 13
IP  - 2
4099  - http://mdc.sagepub.com/content/13/2/19.1.short
4100  - http://mdc.sagepub.com/content/13/2/19.1.full
AB  - The phosphodiesterase type 5 (PDE-5) inhibitor sildenafil failed to improve peak exercise capacity in patients with diastolic heart failure (HF) in a double-blind, placebo-controlled, randomized clinical trial. Results from the Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure trial [RELAX; Redfield MM et al. JAMA 2013] did not replicate the cardiovascular benefits of PDE-5 inhibition obtained in studies of experimental HF and small clinical studies.